Pharma Focus Asia

Merck Invests US$129.48 million (€130) mn to Open New Manufacturing Facility


Merck plans to increase its single-use capacity by opening new manufacturing facility. The new facility will be located in Molsheim, France.


The new site makes use of single-use assemblies, a new key technology for generating Covid-19 vaccines and other lifesaving therapies.

The project features 37,000ft2 ISO7clean rooms, a new logistics warehouse, and an administrative building all expected to be opened by the end of 2024.

The facility aims to expand global manufacturing footprint and bring superior customer value across worldwide. Moreover, it strengthens manufacturing capacity for Mobius® single-use portfolio.

The new project is laid with the biggest investmentin the 50-year history and is expected to be fully operational by 2028.

It is the first site in Europe to manufacture Mobius whereas the other production sites for Mobius are located in Wuxi, China and Danvers, Massachusetts, US.

The new facility is aniticipated to create more than 800 jobs by the end of 2028.


TypeNew Construction
BudgetUS$129.48 million (€130) mn
magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference